BioLargo, Inc. Company Profile

Background

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences company dedicated to developing and commercializing innovative technologies that address environmental challenges. The company's mission is to "make life better" by providing sustainable solutions in water and wastewater treatment, air quality control, industrial odor management, and infection control. With over 13 years of extensive research and development, BioLargo holds a diverse portfolio of issued patents and offers full-service environmental engineering through its subsidiaries.

Key Strategic Focus

BioLargo's strategic focus centers on:

Water and Wastewater Treatment: Developing technologies to remove contaminants such as per- and polyfluoroalkyl substances (PFAS) from water sources.

Air Quality and Odor Control: Providing solutions for industrial odor and volatile organic compound (VOC) management.

Infection Control: Creating advanced wound care and infection control products.

Environmental Engineering Services: Offering comprehensive engineering and consulting services for environmental compliance and process design.

The company targets industries including municipal water treatment, industrial manufacturing, healthcare, and environmental remediation.

Financials and Funding

As of December 31, 2023, BioLargo reported annual revenue of $12.23 million, reflecting significant growth. The company has successfully reduced its debt, retiring over $3 million in 2020 and an additional $650,000 in March 2021. In 2016, BioLargo's subsidiary, Clyra Medical Technologies, secured $750,000 in equity financing and a $5 million operating line of credit from Sanatio Capital LLC to support FDA approval and commercialization of its advanced wound care products.

Pipeline Development

BioLargo's key pipeline developments include:

Aqueous Electrostatic Concentrator (AEC): A technology designed to remove PFAS from water sources, currently in the final stages of development with pilot units being constructed for field testing.

Advanced Oxidation System (AOS): An energy-efficient water treatment technology deployed at a municipal wastewater treatment plant near Montréal, Québec, as part of a demonstration pilot.

BioClynse: A patented, FDA 510(k)-cleared wound irrigation product developed by Clyra Medical Technologies, designed to be gentle yet effective without generating antimicrobial resistance.

Technological Platform and Innovation

BioLargo's innovation is driven by its proprietary technologies and scientific methodologies:

Proprietary Technologies:

CupriDyne Clean: An industrial odor and VOC control product that eliminates odors without masking them, used in various industries including waste management and cannabis production.

Pooph: A pet odor control product that is safe for use around pets and humans, marketed through a branding company and available through retailers like Chewy and Amazon.

Scientific Methods:

Advanced Oxidation Processes: Utilized in the AOS to efficiently remove contaminants from water.

Electrostatic Concentration: Employed in the AEC to target and remove PFAS compounds from water sources.

Leadership Team

BioLargo's leadership comprises experienced professionals:

Dennis P. Calvert: Chairman of the Board, President, and Chief Executive Officer.

Kenneth Code: Chief Science Officer, inventor of BioLargo's core technologies.

Joseph Provenzano: Senior Vice President of Operations.

In February 2023, Clyra Medical Technologies added two medical industry veterans to its board:

Nicholas Valeriani: Former executive at Johnson & Johnson with extensive experience in the medical device industry.

Linda Park: Corporate Secretary, Senior Vice President, and Associate General Counsel at Edwards Lifesciences, with over 20 years of experience in corporate governance and strategic advising.

Competitor Profile

BioLargo operates in a competitive landscape with several key players:

OriginClear: Specializes in water treatment solutions, focusing on modular water treatment systems.

Newterra: Provides modular water, wastewater, and groundwater treatment solutions.

FRC Systems: Offers industrial wastewater treatment solutions, including dissolved air flotation systems.

The market for environmental technologies is expanding, driven by increasing regulatory requirements and the need for sustainable solutions. BioLargo's focus on innovative, cost-effective technologies positions it to compete effectively in this growing market.

Strategic Collaborations and Partnerships

BioLargo has established significant partnerships to enhance its market position:

Garratt-Callahan: A national industrial water treatment company collaborating with BioLargo to develop and sell custom wastewater treatment equipment.

BKT South Korea: A strategic partner working with BioLargo to expand sales of its products.

Operational Insights

BioLargo's operational strategy leverages its subsidiaries to address various environmental challenges:

ONM Environmental: Focuses on air quality and odor control solutions, including the CupriDyne Clean product line.

BioLargo Engineering: Provides full-service environmental engineering and consulting services.

Clyra Medical Technologies: Develops advanced wound care and infection control products.

This diversified approach allows BioLargo to offer comprehensive solutions and adapt to market demands effectively.

Strategic Opportunities and Future Directions

BioLargo is poised for growth through:

Commercialization of PFAS Treatment Technologies: Advancing the AEC to address the growing need for PFAS remediation in water sources.

Expansion of Odor Control Solutions: Increasing market penetration of products like CupriDyne Clean and Pooph.

Advancement in Medical Products: Bringing BioClynse and other medical technologies to market through Clyra Medical Technologies.

By leveraging its innovative technologies and strategic partnerships, BioLargo aims to solidify its position as a leader in the cleantech and life sciences sectors.